Bicara Therapeutics (BCAX) vs Vericel (VCEL)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Vericel (VCEL) has outperformed Bicara Therapeutics (BCAX) over the past year, gaining 17.3% versus a loss of 4.1%. Vericel is the larger company by market cap ($2.05 billion vs $1.14 billion), about 1.8 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BCAX | VCEL |
|---|---|---|
| Share price | $17.26 | $40.05 |
| Market cap | $1.14B | $2.05B |
| 1-day change | +5.12% | -1.69% |
| YTD return | +2.55% | +11.22% |
| 1-year return | -4.11% | +17.35% |
| 5-year return | — | -21.15% |
| P/E ratio (TTM) | — | 85.21 |
| Forward P/E | — | 47.34 |
| EPS (TTM) | $-3.08 | $0.47 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $30.99 | $49.32 |
| 52-week low | $13.70 | $28.95 |
| Distance from 52-week high | -44.30% | -18.80% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +105.68% | +51.24% |
| Average volume | 623.17K | 502.23K |
| Shares outstanding | 66.17M | 51.21M |
| Employees | 103 | 398 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- VCEL has outperformed BCAX by 21.5 percentage points over the past year.
About Bicara Therapeutics
BCAX stock →Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody bound to human transforming growth factor beta for the treatment of solid tumors.
Healthcare · Biotechnology · 103 employees
About Vericel
VCEL stock →Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies and specialty biologic products for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults and pediatric patients with deep partial-thickness and/or full-thickness thermal burns.
Healthcare · Biotechnology · 398 employees
BCAX vs VCEL FAQ
Which is bigger, Bicara Therapeutics or Vericel?
Vericel (VCEL) is larger, with a market capitalization of $2.05B compared with $1.14B for Bicara Therapeutics (BCAX).
Which stock has performed better over the past year, BCAX or VCEL?
VCEL returned +17.35% over the past 12 months, compared with -4.11% for BCAX (price return, excluding dividends). Past performance does not predict future results.
Are Bicara Therapeutics and Vericel in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.